In this ninth update to the living guideline on COVID-19 therapeutics, the World Health Organization evaluates the use of nirmatrelvir/ritonavir for nonsevere COVID-19 and revises prior recommendations regarding the use of remdesivir.
Graham M. Snyder, MD, MS, provides further insight into a study that evaluated the effects of an early return-to-work program that reduced the quarantine period for clinicians who remained asymptomatic after exposure to COVID-19.
Researchers conducted an external validation study to determine whether a machine learning model accurately predicts the risk for clinical deterioration in patients hospitalized with COVID-19 infection.
In this Q&A, Erica Johnson, MD, discussed the transition from pandemic to endemic in regard to COVID-19 infection.
Researchers conducted a study to assess patient factors associated with appendectomy within days of initiating antibiotic treatment for appendicitis.
Researchers conducted a study that compared voter turnout between physicians and the general population for US elections held between 2000 and 2020.
In this Q&A, Erica Johnson, MD, provides insight into the new oral antiviral medications that may soon be approved for the treatment of COVID-19.
Researchers sought to assess the risk for COVID-19-related hospitalization or death among patients with immune-mediated inflammatory diseases receiving treatment with tumor necrosis factor inhibitors.
Investigators conducted a study that compared serum cytokine concentrations and differences in immunity profiles in children hospitalized with SARS-CoV-2 infection.
Researchers sought to compare the risk for hospital and emergency department admission for the treatment of COVID-19 among patients infected with the Alpha variant vs those with the Delta variant.
